2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 762

Pragmatic Treatment of Patients with Systemic Lupus Erythematosus with Rituximab: Long-Term Effects on Serum Immunoglobulins
Abstract Number: 351

Pre-Operative Magnetic Resonance Imaging Can Help in Predicting Two-Year Readmission in Acute Severe Osteoporotic Vertebral Fracture after Vertebroplasty
Abstract Number: 1932

Precapillary Pulmonary Hypertension in Granulomatosis with Polyangiitis: A Case Series with Long-Term Follow-up
Abstract Number: 536

Precision Medicine in Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis on the Diagnostic Accuracy of Anti-CCP Tests for the Diagnosis of Rheumatoid Arthritis
Abstract Number: 2278

Precision of Gout Definitions for Population-Based Genetic Studies: Analysis of the UK Biobank
Abstract Number: 2639

Predicting Flare and Sustained Clinical Remission after Adalimumab Withdrawal Using the Multi-Biomarker Disease Activity (MBDA) Score
Abstract Number: 3089

Predicting the Response to TNF Inhibition or B Cell Depletion Therapy from Peripheral Whole Blood Gene Expression Profiles in Patients with Rheumatoid Arthritis
Abstract Number: 1871

Predicting Vascular Complications in Systemic Sclerosis: A Prospective Cohort Study
Abstract Number: 2650

Prediction of Inhibition of Radiographic Progression By Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of a Global, Phase 3 Trial
Abstract Number: 2341

Prediction of Triaxial Accelerometer Counts from Unaxial Acceleromenter Counts Among Adults with or at Risk for Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Abstract Number: 3092

Predictive Factors for Better Outcome of Switching of Biologics for Patients with Rheumatoid Arthritis in Daily Clinical Practice
Abstract Number: 301

Predictive Factors for Response to Ultrasound-Guided Intra-Articular Glucocorticoids in Knee Osteoarthritis
Abstract Number: 2010

Predictive Factors of Adherence to Treatment in an International Prospective Study of Blood Hydroxychloroquine Levels in SLE Patients with Flares
Abstract Number: 2460

Predictive Factors of Good Response to Conventional Dmards in Patients with Early Seronegative Rheumatoid Arthritis: Data from the Espoir Cohort
Abstract Number: 2648

Predictive Role of Biomarkers for the Response to Biologic Therapy in Rheumatoid Arthritis. Old, New and How Future Looks like?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].